Loading…
Loading…
Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the sale of its European subsidiaries, being Khiron Europe GmbH ("Khiron Europe"), Zerenia Clinics Limited ("Zerenia UK"), PharmaDrug Production GmbH ("Pharmadrug"), Khiron Life Sciences UK Limited ("Khiron UK") and Khiron Life Sciences Spain SL ("Khiron Spain", and collectively with Khiron Europe, Zerenia UK, Pharmadrug and Khiron UK, the "Subject Subsidiaries", and each, a "Subject Subsidiary") to 2518542 Alberta Ltd. (the "Purchaser"), a company controlled by Avonlea-Drewry Holdings Inc. for an aggregate base purchase price of $3,000,000 (the "Transaction").
Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTC Pink: KHRNF) ("Khiron" or the "Company") today announced that the Company and 2518542 Alberta Ltd., a company controlled by Avonlea Drewry Holdings Inc. (the "Purchaser"), have entered into an amended and restated share purchase agreement (the "Restated Purchase Agreement") dated November 15, 2023, providing for the purchase and sale of the Company's European subsidiaries.
TORONTO, May 6, 2023 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company“) (TSXV: KHRN) (OTCQX: KHRNF) announced today that, further to its press release dated April 17, 2023, the Ontario Securities Commission (the “OSC“) has denied the Company’s application for a management cease trade order (the “MCTO“) in connection with its delay in […]...
Khiron Life Sciences Corp. (OTCQX:KHRNF) Q3 2022 Earnings Conference Call November 30, 2022 11:00 AM ET Company Participants Alvaro Torres - CEO and Co-Founder Helen Bellewood - Interim CFO Franziska Katterbach - President-Europe Operator [Call Starts Abruptly] speakers' remarks, we will conduct a questions-and-answer session, a quick one, about six minutes and all participants can submit questions via the chat and the Q&A function on the webcast. On the chat with me today are Alvaro Torres, CEO and Director; Helen Bellewood, CFO; and Franziska Katterbach as Khiron European President.
TORONTO , Nov. 18, 2022 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMXC), the global leader in medical cannabis throughout Latin America and Europe, today announces that it will host a Conference Call on November 30, 2022 at 11:00 a.m. eastern time to discuss its results for the third quarter ended September 30, 2022.
Khiron Life Sciences Corp. (OTCQX:KHRNF) Q2 2022 Earnings Conference Call August 29, 2022 10:00 AM ET Company Participants Paola Ricardo - Investor Relations Alvaro Torres - CEO and Co-Founder Helen Bellewood - Interim CFO Franziska Katterbach - President-Europe Paola Ricardo Okay. Good morning, everyone.
PharmaDrug Inc said it is one step closer to streamlining its focus into a pure-play biotech company with the closing of the sale of its cannabis assets. The company said it has closed the previously announced sale of all of the issued and outstanding securities of Pharmadrug Production GmbH, a German medical cannabis distributor, to Khiron Life Sciences Corp. (OTCQX:KHRNF, TSX-V:KHRN) Pursuant to the terms of the transaction, Khiron issued to Pharmadrug 5,500,000 shares of the company at a deemed price of $0.16 per share and an additional 468,750 shares in connection with certain closing adjustments for a total of 5,968,750 common shares.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTC: KHRNF) has priced and sized its overnight marketed public offering. The company intends to issue 26.70 million units at C$0.15 per unit for gross proceeds of C$4.01 million.
No recent filings indexed.